No Detail Found!

Retrospective analysis of eficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer

Author(s)
Xin Zhang Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Qian Li Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China
Kuan Liu Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China
Hong-yun Shi Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China
Abstract
Objective: Retrospective study and analysis of the safety and eficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer. Methods: A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Afiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent eficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side efects. Results: The diference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant( P>0.05), and the CR of the observation group was significantly higher than that of the control group(P0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(P<0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(P<0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group( P<0.05). Conclusions: Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.
Publication Details
Page(s) 1695-1701
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
Cervical Cancer, Synchronous radiotherapy, Recombinant human Rh-endostatinstatin
References
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Cancer J Clin A,Chen W,Zheng R,Baade PD,Zhang S,Zeng H,Bray F .2016 .GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics, 10(2) : 115-132.
Mansha MA,Sadaf T,Waheed A,Munawar A,Rashid A,Chaudry SJ .2020 .Long-Term Toxicity and Efficacy of Intensity-Modulated Radiation Therapy in Cervical Cancers: Experience of a Cancer Hospital in Pakistan. JCO Glob Oncol, 10 : 1639-1646.
Wassie M,Argaw Z,Tsige Y,Abebe M,Kisa S.,Majeed AI,Ullah A,Jadoon M,Ahmad W,Zielińska W,Mikołajczyk K,Zabrzyński J,Krajewski A,Klimaszewska-Wiśniewska A,Zhang XB,Yang YY,Zeng Y,Zeng HQ,Fu BB,Ko CY,Wu T,Duan X,Hu T,Mu X,Jiang G,Cui S .2020 .Effect of endostatin on Wnt pathway of stem-like cells in bladder cancer in tumor microenvironment. Mol Biol Rep, 10(5) : 3937-3948.
Liang K,Liu Q,Li P,Han Y,Bian X,Tang Y .2018 .Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models. Cancer Gene Ther, 10(7-8) : 167-183.
Tang H,Fu Y,Lei Q,Han Q,Ploplis VA,Castellino FJ .2009 .Fibrinogen facilitates the anti-tumor effect of nonnative endostatin. Biochem Biophys Res Commun, 01(2) : 249-253.
Liu X,Nie W,Xie Q,Chen G,Li X,Jia Y .2017 .Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma. Oncol Lett, 10(2) : 1874-1880.
El-Rehim Abd,Osman DM,NA DM .2014 .Expression of a disintegrin and metalloprotease 8 and endostatin in human osteosarcoma: implication in tumor progression and prognosis. J Egypt Natl Canc Inst, 11(1) : 1-9.
Zhuo W,Chen Y,Song X,Luo Y. .2011 .Endostatin specifically targets both tumor blood vessels and lymphatic vessels. Front Med, 10(4) : 336-340.
Hai-Tao Z,Hui-Cheng L,Zheng-Wu L,Chang-Hong G. .2011 .A tumorpenetrating peptide modification enhances the antitumor activity of endostatin in vivo. Anticancer Drugs, 10(5) : 409-415.
Karaca O,Ertekin T,Canoz O,Ulger H,Soysal H,Kus I .2011 .Effect of endostatin on 1,2-dimethylhydrazine-induced colon tumor in mice. Toxicol Ind Health, 10(1) : 21-26.
Li Y,Wu X,Wang D,Li P,Liang H,Yan Hu X .2022 .Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome. J Clin Transl Hepatol, 10(5) : 1150-1160.
He X,Hu X,Dong X,Li S,Ni Y. .2022 .Application and clinical efficacy of Sufu medical chitosan hydrogel dressing in radiation skin damage caused by radiotherapy for cervical cancer. Pak J Med Sci, 10(8) : 5569-2336.
Chen Z,Shi Y,Wang S,Lu Q .2017 .Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients. Oncotarget, 10(35) : 59609-59617.
Chen Q,Chen Y,Li X,Liu H,Sun X. TRIB3 .2022 .Interacts with STAT3 to Promote Cancer Angiogenesis. Curr Med Sci, 10(5) : 932-940.
Zhao M,Guan P,Xu S,Lu H .2023 .Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy via Blocking Vascular Endothelial Growth Factor Signaling. Nano Lett, 10(18) : 8674-8682.
Li N,Wang Z,Yuan G,Sun Y,Zhang R,Li X .2020 .An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. J Oncol, 10 : .
Zhang S,Han C,Sun L,Huang L,Ma J .2020 .Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. Radiat Oncol, 10(1) : 205.
Ding RL,Xie F,Hu Y,Fu SZ,Wu JB,Fan J .2016 .Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model. Drug Deliv, 10(1) : 300-308.
Zambon L,Honma HN,Lourenço GJ,Saad IA,Mussi RK,Lima CS .2007 .A polymorphism in the angiogenesis inhibitor, endostatin, in lung cancer susceptibility. Lung Cancer, 10(2) : 276-278.
0

Citations

0

Downloads

71

Views